LENZ Therapeutics, Inc. (LENZ) Stock Score, Valuation & Financial Research

LENZ Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LENZ

LENZ Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.84. These figures are a research snapshot, not a buy or sell recommendation.

What LENZ Therapeutics, Inc. does

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

LENZ Therapeutics is a biopharmaceutical company focused on the development and commercialization of ophthalmic pharmaceutical products. The company generates value by bringing proprietary eye drop treatments for presbyopia to market, relying on regulatory approval, commercial distribution networks, and prescriber uptake to drive revenue.

Products and services

  • The company's primary product is VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop treatment for presbyopia.

Brands and product families

  • VIZZ — Aceclidine ophthalmic solution for the treatment of presbyopia. Source

Annual revenue by business

  • License: USD 17,500,000 · 91.68% calculated revenue share (period 2025-12-31) Source
  • Product: USD 1,588,000 · 8.32% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Ophthalmologists; Optometrists.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its pharmaceutical products; specific supplier names are unnamed. Source

Business strengths to evaluate

  • Proprietary aceclidine-based ophthalmic technology Source
  • Experienced management team with industry background Source

Business risks and research considerations

  • Dependence on third-party manufacturers for product supply Source
  • Intense competition in the presbyopia treatment market Source
  • Potential for adverse safety events in real-world use Source

Sources: Company research source · License · Experienced management team with industry background · Intense competition in the presbyopia treatment market · Potential for adverse safety events in real-world use

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LENZ financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.84
Market capitalization:
120.24M (currency not supplied)
Revenue:
USD 21.48M
Net income:
USD -126M
Free cash flow:
USD -70M
Cash:
USD 24.21M
Total debt:
USD 122K
EPS:
USD -4.09

What stands out

  • Reported year-over-year revenue growth is +12.5%.
  • Free cash flow is USD -70M, negative for the stored period.
  • The balance sheet shows USD 24.21M of cash versus USD 122K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -325.9% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -586.7% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 24.09M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LENZ

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can LENZ maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can LENZ fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LENZ likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LENZ to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of LENZ's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research LENZ

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.